Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Preston

Showing results (491-500 of 718) with videos related to

Pageof 72
Sort By:
Hypertension (Dallas, Tex. : 1979)|February 8, 2003
Effects of severe hypertension on endothelial and platelet microparticlesRichard A Preston, Wenche Jy, Joaquin J Jimenez, et al.
JAMA|October 20, 1998
Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsR A Preston, B J Materson, D J Reda, et al.
Journal of Hypertension|April 1, 2026
Acute blood pressure reduction exceeding safety and autoregulatory limits following rapid-acting antihypertensives for hypertensive urgencyRichard A Preston, Evelyn V Caizapanta, David Afshartous, et al.
European Urology|February 13, 2017
Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health StudyMary K Downer, Christopher B Allard, Mark A Preston, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 14, 2001
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countriesS I Bandak, M R Turnak, B S Allen, et al.
Journal of Clinical Pharmacology|August 30, 2016
Clinical Pharmacology of Delafloxacin in Patients With Hepatic ImpairmentRandall Hoover, Thomas C Marbury, Richard A Preston, et al.
Antimicrobial Agents and Chemotherapy|December 22, 2017
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative SubjectsMatthew P Kosloski, Weihan Zhao, Thomas C Marbury, et al.
European Journal of Clinical Pharmacology|April 25, 2012
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairmentPaul Statkevich, Teddy Kosoglou, Richard A Preston, et al.
Kidney International|May 3, 2000
ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cellsW F Pendergraft, D A Alcorta, M Segelmark, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 14, 2011
The association between tumour density and prostate cancer recurrence following radical prostatectomyLuke T Lavallée, Rodney H Breau, Mark A Preston, et al.
Pageof 72

Showing results (491-500 of 718) with videos related to

Sort By:
Pageof 72
Hypertension (Dallas, Tex. : 1979)|February 8, 2003
Effects of severe hypertension on endothelial and platelet microparticlesRichard A Preston, Wenche Jy, Joaquin J Jimenez, et al.
JAMA|October 20, 1998
Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsR A Preston, B J Materson, D J Reda, et al.
Journal of Hypertension|April 1, 2026
Acute blood pressure reduction exceeding safety and autoregulatory limits following rapid-acting antihypertensives for hypertensive urgencyRichard A Preston, Evelyn V Caizapanta, David Afshartous, et al.
European Urology|February 13, 2017
Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health StudyMary K Downer, Christopher B Allard, Mark A Preston, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 14, 2001
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countriesS I Bandak, M R Turnak, B S Allen, et al.
Journal of Clinical Pharmacology|August 30, 2016
Clinical Pharmacology of Delafloxacin in Patients With Hepatic ImpairmentRandall Hoover, Thomas C Marbury, Richard A Preston, et al.
Antimicrobial Agents and Chemotherapy|December 22, 2017
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative SubjectsMatthew P Kosloski, Weihan Zhao, Thomas C Marbury, et al.
European Journal of Clinical Pharmacology|April 25, 2012
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairmentPaul Statkevich, Teddy Kosoglou, Richard A Preston, et al.
Kidney International|May 3, 2000
ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cellsW F Pendergraft, D A Alcorta, M Segelmark, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 14, 2011
The association between tumour density and prostate cancer recurrence following radical prostatectomyLuke T Lavallée, Rodney H Breau, Mark A Preston, et al.
Pageof 72